Michael Hennigan, MD
Endocrinology, Diabetes & Metabolism · Fairhope, ALNPI 1003971839
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Bayer at 46.0% of the total. Reporting peaked in 2021 at $8,308 and has fallen 82.6% since, to $1,450 in 2025.
Across 314 payments — averaging $78.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$11K
- Gilead$5K
- Amgen$2K
- Novo Nordisk$1K
- Lilly USA, LLC$826
- Boehringer Ingelheim$520
- plus $4K from 33 others
What the payments were for
- Consulting fees$3,00012%
- Speaking & faculty fees$10,68543%
- Travel & lodging$2,93612%
- Food & beverage$7,94032%
- Education$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $11,387 |
| Gilead | 11 | $4,945 |
| Amgen(2 entities) | 48 | $1,915 |
| Novo Nordisk | 62 | $1,390 |
| Lilly USA, LLC | 40 | $826 |
| Boehringer Ingelheim | 20 | $520 |
| Amarin Pharma, Inc. | 16 | $405 |
| Insulet Corporation | 4 | $392 |
| Sanofi US Services Inc. | 1 | $350 |
| Novartis | 15 | $340 |
| Merck | 12 | $291 |
| AbbVie | 11 | $237 |
| Corcept Therapeutics | 10 | $214 |
| BETA Bionics, Inc. | 2 | $176 |
| Regeneron Healthcare Solutions, Inc. | 2 | $145 |
| Dexcom, Inc. | 7 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Sanofi-aventis U.S. LLC | 3 | $110 |
| Medtronic(2 entities) | 5 | $93 |
| IBSA Pharma Inc. | 4 | $80 |
| Tandem Diabetes Care, Inc. | 1 | $74 |
| AstraZeneca(2 entities) | 4 | $71 |
| Shire North American Group Inc | 1 | $71 |
| Abbott | 3 | $51 |
| Radius Health, Inc. | 1 | $51 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Neurocrine Biosciences, Inc. | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Sanofi Pasteur Inc. | 1 | $30 |
| Antares Pharma, Inc. | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kvk-tech, Inc. | 2 | $8 |
| Johnson & Johnson | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$11,220
- iLet Bionic Pancreas$433
- TEPEZZA$374
- SOLIQUA 100/33$350
- Ozempic$347
- Omnipod$300
- Repatha$248
- EVENITY$227
- iLet Insulin Infusion Kit Inset$144
- iLet Insulin Infusion Kit Contact Detach$144
- INVOKANA$125
- JARDIANCE$121
- EVKEEZA$109
- STEGLATRO$109
- Prolia$102
- XGEVA$102
- RYBELSUS$102
How this compares
$24,761 in reported general payments places this provider in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 225 | $251,841 |
| OzempicSemaglutide | 216 | $235,680 |
| JardianceEmpagliflozin | 198 | $212,589 |
| FarxigaDapagliflozin Propanediol | 93 | $91,313 |
| Repatha SureclickEvolocumab | 75 | $69,119 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $61,005 |
| ForteoTeriparatide | 13 | $57,995 |
| TrulicityDulaglutide | 36 | $55,024 |
| RybelsusSemaglutide | 26 | $41,361 |
| KerendiaFinerenone | 22 | $26,084 |
| Repatha PushtronexEvolocumab | 22 | $13,939 |
| Ezetimibe | 284 | $8,416 |
| Pioglitazone Hcl | 329 | $4,568 |
| Rosuvastatin Calcium | 174 | $2,875 |
| Levothyroxine Sodium | 233 | $2,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $826 | $364,859274 claims |
| Novo NordiskOzempic, Rybelsus | $1,390 | $277,042242 claims |
| Boehringer IngelheimJardiance | $520 | $212,589198 claims |
| AstraZenecaFarxiga | $71 | $91,31393 claims |
| BayerKerendia | $11,387 | $26,08422 claims |
| AbbVieSynthroid | $237 | $2,44531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Fairhope
- Judson MenefeeFairhope$168K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.